Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 121.60
Bid: 121.60
Ask: 122.00
Change: 1.20 (1.00%)
Spread: 0.40 (0.329%)
Open: 121.00
High: 122.00
Low: 120.40
Prev. Close: 120.40
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: All change at Aura Energy amid ASX spin-out plan

Mon, 22nd Nov 2021 15:57

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News:

----------

Aura Energy Ltd - gold and uranium explorer in Sweden and Mauritania - Revamps board and management as part of push to become a uranium producer. Phil Mitchell, a former Rio Tinto PLC and Anglo American PLC executive, will be named non-executive chair at Aura's annual general meeting on December 21. Peter Reeve will leave the board, as he moves from chief executive officer of Aura to CEO of wholly owned gold subsidiary Archaean Greenstone Gold Pty Ltd. Reeve will lead the spin-out of Archaean as a separate listing on the ASX in Sydney in 2022. Aura shareholders will received shares in Archaean as part of the process. Aura will look for a new CEO within six months to focus on taking the Tiris uranium project in Mauritania into production. Warren Mundine and Bryan Dixon, both accountants experienced in junior mining companies, will become independent non-executive directors, while Martin Rogers and Peter Ward will depart the board at the AGM.

----------

Jersey Oil & Gas PLC - explorer in UK North Sea - Installs former leadership team of Ithaca Energy, a North Sea oil and gas producer that had been listed on AIM, in senior positions. Promotes Non-Executive Director Les Thomas to chair, replacing Marcus Stanton, who will remain as a non-executive director. Thomas was CEO of Ithaca until 2020. Hires Graham Forbes as chief financial officer. Forbes had been CFO of Ithaca. Richard Smith, who was corporate development director at Ithaca, joins Jersey Oil as chief commercial officer. All effective immediately. Company says it remains in active discussions with "multiple counterparties" regarding the farm-out of the Greater Buchan Area in the central North Sea.

----------

Xpediator PLC - Braintree, England-based freight management services provider in UK and central and eastern Europe - Rob Ross steps down as CEO immediately, with Non-Executive Director Wim Pauwels made interim CEO while a search for a successor is conducted. Ross had joined Xpediator as CFO at the start of 2020. Pauwels formerly was chief regional officer for Yusen Logistics Europe. Xpediator says trading remains positive and in line with market expectations for the full year.

----------

e-Therapeutics PLC - Oxford, England-based computational drug discovery - Karl Keegan will step down as CFO on December 31 "to focus in the near term on extremely difficult family circumstances in Ireland". Non-Executive Director Michael Bretherton will become interim CFO while the company looks for a new CFO. Bretherton, a former PriceWaterhouse accountant, has been a director of seven other AIM-listed companies, e-Therapeutics notes.

----------

Grainger PLC - Newcastle-based residential landlord - Promotes Eliza Pattinson to director of investments for asset management, managing Grainger's portfolio of 9,727 rental homes, effective immediately. Rehires Steven Clark as director of investments for acquisitions. Clark joins in mid-February next year from Lendlease Europe, where he is residential investment director. He had left Grainger as commercial finance director in April 2020.

----------

Hiscox Ltd - Hamilton, Bermuda-based insurer - Hires Donna DeMaio as independent non-executive director, replacing Caroline Foulger, who will retire at the 2022 annual general meeting after nine years. Hiscox holds its AGM in May. DeMaio was chief operating officer for American International Group Inc's General Insurance division.

----------

Syncona Ltd - investment trust focused on healthcare - Hires Julie Cherrington and Cristina Csimma as non-executive directors, starting February 1 next year. Cherrington was CEO of biotechnology companies in the US, Canada and Australia, including Arch Oncology and Que Oncology. Csimma is executive chair of drug developer Forendo Pharma Ltd.

----------

Great Western Mining Corp PLC - gold, silver and copper explorer and developer in US state of Nevada - Hires James Blight as exploration manager, joining next Monday. Blight is a qualified person for mineral reporting purposes and has worked on projects in West Africa, Saudi Arabia, Ethiopia, Mongolia and Sweden.

----------

Utilico Emerging Markets Trust PLC - invests in infrastructure, utilities and related sectors in emerging markets - Hires Isabel Liu as independent non-executive director, starting immediately. Liu is an experienced infrastructure investor, Utilico says. She was managing director of the Asia-Pacific investment business of recently acquired infrastructure investor John Laing Group PLC and currently is a non-executive director of Schroder Oriental Income Fund Ltd.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
11 Apr 2024 14:22

Syncona agrees to sell stake in investee company for GBP7.4 million

(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc.

Read more
4 Apr 2024 17:06

IN BRIEF: Syncona notes investee Achilles's annual loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles.

Read more
14 Mar 2024 14:16

Syncona portfolio company Autolus posts widened loss for 2023

(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.

Read more
12 Feb 2024 18:01

IN BRIEF: Freeline shareholders approve Syncona acquisition

Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.

Read more
8 Feb 2024 13:45

UPDATE: Syncona portfolio strengthens thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes.

Read more
8 Feb 2024 09:41

Syncona portfolio strengthens in third quarter thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies.

Read more
8 Feb 2024 09:04

Syncona NAV grows in Q3

(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.

Read more
22 Jan 2024 12:19

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Read more
19 Jan 2024 08:36

Syncona says Freeline trial for Gaucher disease treatment positive

(Alliance News) - Syncona Ltd on Friday noted Freeline Therapeutics Holdings PLC's positive data for Gaucher disease treatment.

Read more
4 Dec 2023 09:37

IN BRIEF: Syncona notes Beacon's "encouraging" AGTC-501 trial data

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501.

Read more
27 Nov 2023 19:03

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
22 Nov 2023 14:30

IN BRIEF: Syncona agrees to buyout deal with Freeline Therapeutics

Syncona Ltd - London-based investor in healthcare companies - Agrees to acquire all remaining stock in investee Freeline Therapeutics Holdings PLC for USD6.50 in cash per share, valuing Freeline at approximately USD28.3 million. Syncona currently owns 49.7% of shares in Freeline. The company will provide up to USD15 million of financing in conjunction with the acquisition to enable Freeline to meet its near-term cash requirements and continue advancing its lead programme FLT201, a potential gene therapy for Gaucher disease.

Read more
16 Nov 2023 10:34

Syncona reports declining asset value as investment head steps down

(Alliance News) - Syncona Ltd on Thursday said net asset value decreased as it swung to a negative return in its latest half year, but that it is well-positioned for future growth thanks to its "rich pipeline".

Read more
16 Nov 2023 08:44

Syncona net asset value falls, co-founder steps down

(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.